Core Insights - Climb Bio, Inc. has appointed Dr. Perrin Wilson as Chief Business Officer, bringing over 17 years of experience in the pharmaceutical and biotech industry [1][2] - Dr. Wilson will lead pre-commercial planning, communications, and business development efforts, focusing on advancing treatments for immune-mediated diseases [2] - The company is currently developing two key assets: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy [3] Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on therapeutics for patients with immune-mediated diseases [3] - The pipeline includes budoprutug, which has shown B-cell depletion potential, and CLYM116, which is in IND-enabling studies [3] Leadership Background - Dr. Wilson previously served as Senior Vice President at Nuvalent and held various roles at Forma Therapeutics/Novo Nordisk, including leading a $1.1 billion acquisition [2] - She has extensive experience in business development and strategy, including a $5.2 billion acquisition at Takeda [2]
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer